{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T14:10:59Z","timestamp":1779286259410,"version":"3.51.4"},"reference-count":15,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.clinthera.2026.03.015","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T21:11:58Z","timestamp":1776201118000},"page":"539-543","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Mechanism-Driven Repurposing of All-Trans Retinoic Acid (ATRA) for AML1-MTG16\u207a Acute Myeloid Leukemia: A First-in-Human Case Report and Translational Roadmap to Overcome the \u201cLong-Tail\u201d Barrier"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8309-5599","authenticated-orcid":false,"given":"Kuangguo","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiqiong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2026.03.015_bib0001","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/ajh.27138","article-title":"Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: genotype signatures for response and survival among 301 consecutive patients","volume":"99","author":"Gangat","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clinthera.2026.03.015_bib0002","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1016\/j.clinthera.2010.12.003","article-title":"Economic analysis of decitabine versus best supportive care in the treatment of intermediate- and high-risk myelodysplastic syndromes from a US payer perspective","volume":"32","author":"Pan","year":"2010","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2026.03.015_bib0003","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1080\/17474086.2024.2402283","article-title":"Relapse and resistance in acute myeloid leukemia post venetoclax: improving second lines therapy and combinations","volume":"17","author":"Shahswar","year":"2024","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.clinthera.2026.03.015_bib0004","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/gm539","article-title":"The translation of cancer genomics: time for a revolution in clinical cancer care","volume":"6","author":"Mardis","year":"2014","journal-title":"Genome Med"},{"key":"10.1016\/j.clinthera.2026.03.015_bib0005","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1007\/s00277-018-3389-3","article-title":"Myeloid neoplasms with t(16;21)(q24;q22)\/RUNX1-RUNX1T3 mimics acute myeloid leukemia with RUNX1-RUNX1T1","volume":"97","author":"Liu","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clinthera.2026.03.015_bib0006","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1080\/10428194.2025.2603553","article-title":"Adverse outcomes and high incidence of therapy-related neoplasms in patients with the t(16;21)\/RUNX1::RUNX1T3 fusion","volume":"67","author":"Guo","year":"2025","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clinthera.2026.03.015_bib0007","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1002\/hec.1538","article-title":"Drug development costs when financial risk is measured using the Fama-French three-factor model","volume":"19","author":"Vernon","year":"2010","journal-title":"Health Econ"},{"key":"10.1016\/j.clinthera.2026.03.015_bib0008","doi-asserted-by":"crossref","first-page":"8887","DOI":"10.1074\/jbc.RA120.013042","article-title":"The transcriptional corepressor CBFA2T3 inhibits all-trans-retinoic acid-induced myeloid gene expression and differentiation in acute myeloid leukemia","volume":"295","author":"Steinauer","year":"2020","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clinthera.2026.03.015_bib0009","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-41964-y","article-title":"Randomized phase-III study of low-dose cytarabine and etoposide\u2009+\u2009\/- all-trans retinoic acid in older unfit patients with NPM1-mutated acute myeloid leukemia","volume":"13","author":"Schlenk","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.clinthera.2026.03.015_bib0010","doi-asserted-by":"crossref","first-page":"5046","DOI":"10.1038\/sj.onc.1209515","article-title":"Bcl-2 is a key regulator for the retinoic acid-induced apoptotic cell death in neuroblastoma","volume":"25","author":"Niizuma","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.clinthera.2026.03.015_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109182","article-title":"All-trans retinoic acid enhanced the antileukemic efficacy of ABT-199 in acute myeloid leukemia by downregulating the expression of S100A8","volume":"112","author":"Li","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.clinthera.2026.03.015_bib0012","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1007\/s11596-023-2805-7","article-title":"Chidamide, decitabine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor therapy for patients with relapsed\/refractory acute myeloid leukemia: a retrospective study from a single-center","volume":"43","author":"Kong","year":"2023","journal-title":"Curr Med Sci"},{"key":"10.1016\/j.clinthera.2026.03.015_bib0013","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1217701","article-title":"Real-world experience with selinexor-containing chemotherapy-free or low-dose chemotherapy regimens for patients with relapsed\/refractory acute myeloid leukemia and myeloid sarcoma","volume":"14","author":"Tong","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clinthera.2026.03.015_bib0014","first-page":"14","article-title":"Pharmacokinetics of all-trans-retinoic acid: clinical implications in acute promyelocytic leukemia","volume":"31","author":"Adamson","year":"1994","journal-title":"Semin Hematol"},{"key":"10.1016\/j.clinthera.2026.03.015_bib0015","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/s41375-021-01230-4","article-title":"Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerations","volume":"35","author":"Walter","year":"2021","journal-title":"Leukemia"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826000779?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826000779?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T13:35:49Z","timestamp":1779284149000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291826000779"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0149291826000779"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.03.015","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanism-Driven Repurposing of All-Trans Retinoic Acid (ATRA) for AML1-MTG16\u207a Acute Myeloid Leukemia: A First-in-Human Case Report and Translational Roadmap to Overcome the \u201cLong-Tail\u201d Barrier","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.03.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}